Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04332653 |
TitleNT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2020-04-03 |
Location
Florida, United States
Michigan, United States Missouri, United States North Carolina, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Completed
|
Drugs
NT-I7, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03984578 |
TitleWindow of Opportunity Study in Colorectal Cancer | Phase
Phase 2
|
Date Added 2019-06-13 |
Location
Singapore
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04660812 |
TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | Phase
Phase 1, Phase 2
|
Date Added 2020-12-09 |
Location
Arizona, United States
California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy South Korea Spain United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab |
Tags
MSS/ MMRp
|
| NCT ID NCT03388632 |
TitleRecombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | Phase
Phase 1
|
Date Added 2018-01-03 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Completed
|
Drugs
Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04776148 |
TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | Phase
Phase 3
|
Date Added 2021-03-01 |
Location
California, United States
Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Russia South Korea Spain Taiwan Turkey (Türkiye) United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil) |
Tags
MSS/ MMRp
|
| NCT ID NCT03239145 |
TitlePembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Phase
Phase 1
|
Date Added 2017-08-03 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Pembrolizumab, Trebananib |
Tags
MSS/ MMRp
|
| NCT ID NCT03990233 |
TitleA Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Phase
Phase 1
|
Date Added 2019-06-18 |
Location
Belgium
France |
Prior IO Allowed Yes |
CRC-directed No |
Status
Completed
|
Drugs
BI 754091, BI 765063 |
Tags
MSS/ MMRp
|
| NCT ID NCT01351103 |
TitleA Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Phase
Phase 1
|
Date Added 2011-05-10 |
Location
California, United States
Maryland, United States Massachusetts, United States Michigan, United States Texas, United States Canada France Germany Italy Netherlands Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Completed
|
Drugs
LGK974, PDR001 |
Tags
MSS/ MMRp
|
| NCT ID NCT04853017 |
TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) | Phase
Phase 1
|
Date Added 2021-04-21 |
Location
California, United States
Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Completed
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04444622 |
TitleImmunotherapy for Third Line Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-06-23 |
Location
Florida, United States
Michigan, United States New Jersey, United States New York, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs |
Tags
MSS/ MMRp
|
